menu

News & press releases

Thank you for showing an interest in Airsonett.We are committed to changing the lives of people living with allergic diseases. We develop state-of-the art technology to improve lives.

For all press inquiries, please contact: press@airsonett.eu.

To find out more about studies and research on treatment with Air4 by Airsonett, click here.

2018
Airsonett AIR4 maintains good control of severe allergic asthma after withdrawal of omalizumab July 11, 2018

An independent study by Professor C. Wang concludes in the title of the study “A nocturnal temperature controlled laminar flow device (TLA) maintains good control of severe allergic asthma(SAA) after withdrawal of Omalizumab therapy”. The study will be published in a poster session at ERS on Asthma Management session on Sunday 16 September 2018.

“We are naturally very positive to these interesting data and look forward to feedback from the health care sector” says Anders Due-Boje, CEO at Airsonett AB.

Airsonett AB is a medical device company with a unique technology developed to treat patients with severe asthma. The company is active in Europe, the US and recently signed a major co-operation agreement with a Chinese distributor. The company’s product Airsonett AIR4 is a clinically validated, non-pharmaceutical treatment of asthma, which reduces allergens and other airborne irritants from the patient’s breathing zone during the nightly sleep.

Airsonett AB announces that the company has appointed Anders Due-Boje as its new CEO July 4, 2018

Airsonett AB is a medical device company with a unique technology developed to treat patients with severe asthma. The company is active in Europe, the US and recently signed a major co-operation agreement with a Chinese distributor. The company’s product Airsonett AIR-4 is a clinically validated, non-pharmaceutical treatment of asthma, which reduces allergens and other airborne irritants from the patient’s breathing zone during the nightly sleep.

Anders Due-Boje took up his position as CEO in 18 June. Anders has experience in developing both SME’s and larger corporations on a global level in the Medical Device and Information Industry and he has a strong sales and marketing focus. Anders has had leading positions within various companies, among others Neoventa Medical, GN Netcom och Motorola.

“Anders has more than 25 years’ international experience from management positions in the Medical Device and Information industry and he will be able to assist the company to take the next step in a successful development” says Magnus Lundberg, Chairman at Airsonett AB.

Airsonett recently signed agreement with distributor in Germany April 26, 2018

“Germany is one of our key markets so we are pleased to have signed a distribution agreement with the medical device company OxyCare GmbH. The company is dedicated to promote and launch Airsonett AIR4 on the German market. OxyCare will not only market AIR4 but also handling all logistics,installations and training for the German market. We are very pleased that we now have a partner that can introduce the AIR4 in Germany and help more people benefit from this treatment.” says Jonas Båghammar, VP Business Development at Airsonett AB.

Airsonett AB is a medical device company with a unique technology developed to treat patients with severe allergic asthma or eczema. The company is active in Europe, the US and recently signed a major co-operation agreement with a Chinese distributor. The company’s product Airsonett AIR4 is a clinically validated, non-pharmaceutical treatment, which reduces allergens and other airborne irritants from the patient’s breathing zone during the nightly sleep.

New eczema study with Airsonett AIR4 published March 13, 2018

Promising results from an independent prospective pilot study lead by Dr. Claudia Gore, Imperial College, London has recently been published. The study showed that treatment with Temperature controlled Laminar Airflow (TLA; Airsonett AIR4) can lead to a significant clinical improvement in children and adolescents with severe allergic eczema, with accompanying reduction in medication usage.

Allergic eczema (also called atopic dermatitis) is a chronic inflammatory skin disease affecting up to 20% of children. Severe allergic eczema inflicts a substantial burden on patients and their families. Children and parents are burdened with time-consuming topical treatment regimens. In addition, many families must deal with a significant loss of sleep related to night-time itching and scratching.

The TLA device has previously been shown to significantly reduce the number of inhaled allergens and other potential trigger factors in the breathing zone over night, leading to decreased symptoms and improved quality of life in patients suffering from allergic asthma.

The current study was designed to evaluate the effectiveness of overnight treatment with the TLA device (Airsonett AIR4) in children and adolescents with severe allergic eczema over a 12-month period.

Fifteen children (2-16 years) with longstanding severe allergic eczema (atopic dermatitis) were followed during a 12-month treatment period. The study results included significant improvements in SCOR ring of Atopic Dermatitis (SCORAD) index, Investigator Global Assessment (IGA) and Family Dermatology Quality of Life index (FDQLI) after 12 months treatment. Importantly, the clinical improvement was accompanied by a reduction in the use of potent topical corticosteroids.

“We have many reports from patients with severe allergic eczema whose symptoms have improved substantially with AIR4 and it is very positive that this study supports those observations.” says JonasBåghammar, VP Business Development at Airsonett AB.

2017
Treatment with Airsonett AIR4 has sustained benefit in children and adolescents with severe allergic eczema (atopic dermatitis) June 21, 2017

Promising results from an independent prospective pilot study lead by Dr. Claudia Gore, Imperial College, London, was presented Tuesday afternoon at the ongoing EAACI congress in Helsinki. The study showed that treatment with Temperature controlled Laminar Airflow (TLA; Airsonett) can lead to a significant clinical improvement in children and adolescents with severe allergic eczema, with accompanying reduction in medication usage.

Allergic eczema (also called atopic dermatitis) is a chronic inflammatory skin disease affecting up to 20% of children. Severe allergic eczema inflicts a substantial burden on patients and their families. Children and parents are burdened with time-consuming topical treatment regimens. In addition, many families have to deal with a significant loss of sleep related to night-time itching and scratching.

The TLA device has previously been shown to significantly reduce the amount of inhaled allergens and other potential trigger factors in the breathing zone over night, leading to decreased symptoms and improved quality of life in patients suffering from allergic asthma.

The current study was designed to evaluate the effectiveness of overnight treatment with the TLA device (Airsonett) in children and adolescents with severe allergic eczema over a 12-month period. Fifteen children (2-16 years) with longstanding severe allergic eczema (atopic dermatitis) were followed during a 12-month treatment period. The study results included significant improvements in SCOR ring of Atopic Dermatitis (SCORAD) index, Investigator Global Assessment (IGA) and Family Dermatology Quality of Life index (FDQLI) after 12 months treatment. Importantly, the clinical improvement was accompanied by a reduction in the use of potent topical corticosteroids.

Airsonett AIR4 can generate significant cost savings while still maintaining asthma-related quality of life according to an independent expert review February 22, 2017

An independent expert review authored by John O Warner, Professor of Paediatrics, Imperial College London, was today published on-line in Therapeutic Advances in Respiratory Disease. The review concludes that temperature-controlled laminar airflow (TLA) treatment (Airsonett AIR4) improves asthma-related quality of life, reduces airway inflammation and the frequency of severe asthma exacerbations in patients with severe allergic asthma. As these patients might otherwise be considered for treatment with expensive biologicals, Prof Warner suggest that employment of Airsonett AIR4 in this patient population could generate significant cost savings while still maintaining quality of life.

Prof Warner has an extensive knowledge of paediatric allergic diseases and a vast experience of using the Airsonett device both in a clinical and research setting. He was a key member of the scientific advisory board designing and over-seeing the conduct of the pivotal 12-month trial and he also lead the scientific team that conducted the health economic analysis recently published. In addition to the comprehensive review of the scientific evidence supporting the efficacy of Airsonett AIR4, Prof Warner also highlights that patients and families are welcoming recommendations on relevant allergen avoidance strategies and that ‘families were very keen to be enrolled’ in the Airsonett study he conducted.

─ As a non-invasive, home based, drug free treatment, Airsonett AIR4 is an attractive therapy for allergic asthma patients. We welcome this independent expert review by Professor John O Warner reinforcing the value that we believe Airsonett AIR4 can bring to patients, their families and the health care system, says Fredrik Werner, CEO, Airsonett AB.

2016
Airsonett increases its focus on global commercial expansion November 23, 2016

Airsonett AB is expanding its International Sales Organization to increase the rate of its commercial expansion by recruiting a new VP Sales and Marketing and appointing a VP Distributor Sales and Business Development. Recently a number of independent expert groups, both in Sweden and the UK, have published positive evaluations of the company’s innovative home based asthma treatment, Airsonett AIR4.1-4 Airsonett AIR4 has in clinical evidence been shown to further reduce airway inflammation and asthma symptoms leading to a significantly better quality of life when added to patients with allergic asthma that remains poorly controlled despite taking conventional pharmacological treatments.

”I am excited to announce that we have been able to recruit Per Persson to lead our International Sales Organisation as our new Vice President Sales & Marketing. Per brings more than 25 years’ of international experience from leading positions within both Sales and Marketing in the Medical Device industry. Most recently he held the position as Vice President Sales at Atos Medical. Per has a strong winning attitude and a personality that will complement and enhance our ability to meet the needs of our customers as we continue to grow” says Fredrik Werner, CEO.

“Sometimes you discover a technology that is adding a huge benefit for patients” says Per Persson. “With the technology offered by Airsonett you are combining the best of worlds; an easy to use medical device that offers additional clinical efficacy with no risk for pharmacological side effects. In the coming years we will focus our efforts on developing our commercial activities and ensure increased access for patients suffering from allergic diseases to this leading technology.”

Jonas Båghammar, who previously had the position of Vice President Sales and Marketing, has beenappointed to take on the new position as Vice President of Distributor Sales and BusinessDevelopment to further broaden and strengthen the opportunities in new markets as well as developing prosperous synergetic business opportunities.

Professor Karl-Christian Bergmann, Charité - Berlin, presented Airsonett data at Allergo 2016 in Cologne April 12, 2016

At Allergo-Update’s annual meeting in Cologne, Prof Karl-Christian Bergmann, Charité – Universitätsmedizin, Berlin, presented the latest Airsonett data as part of his speech on Aerobiology. Professor Bergmann pointed out that according to a recent publications, Airsonett treatment (TLA) decreases the number of emergency emissions and exacerbations for patients with severe allergic asthma. Moreover, for patients with poorly controlled asthma, TLA can significantly improve their airway inflammation, reported Prof Bergmann.

Airsonett AIR4 a cost-effective, drug-free alternative for patients with severe allergic asthma March 23, 2016

An economic analysis, published today in published in BMJ Open Respiratory Research finds Airsonett AIR4 to be a cost-effective addition to treatment options in patients with uncontrolled severe allergic asthma. For high-risk individuals with more severe and less well controlled asthma the use of Airsonett AIR4 to reduce incidence of hospitalisation would be a cost saving to the NHS.

Continuous allergen exposure is a major risk factor of frequent symptoms and exacerbations for patients with allergic asthma. Airsonett AIR4 is a non-pharmacological treatment that uses the unique, patented Temperature controlled Laminar Airflow (TLA) technology to significantly reduce allergens and other airborne irritants from the patient’s breathing zone during night. It has been shown that TLA treatment significantly can reduce allergen exposure and airway inflammation leading to a significantly improved health-related quality of life in patients suffering from poorly controlled severe allergic asthma.

A recently published clinical trial by Professor Uwe Schauer et al. showed that TLA treatment may improve asthma control and reduce exacerbations, emergency room visits and hospitalisations. In the current study, Professor John O Warner and his team used the health service utilisation reported by Schauer et al and English health service costs to quantify the cost-effectiveness of using TLA as an add-on to standard asthma management drug therapy in the UK. The analysis, described in detail in the paper published today in BMJ Open Respiratory Research, conclude that TLA is a cost-effective treatment. For high-risk individuals with more severe and less well controlled asthma the avoidance of two hospital admissions (via A&E or general admission) or one ICU admission per year would result in TLA treatment being cost saving to the NHS.

The current study demonstrates the value of using TLA treatment to prevent exacerbations from the perspective of both the wellbeing of the patient and the economic advantage to the NHS. For patients with uncontrolled severe allergic asthma TLA is a drug-free alternative that may complement or obviate the need for use of expensive and/or potent drug therapies that are associated with a greater risk of side effects, says Professor John O Warner, Professor of Paediatrics, Imperial College London

For the patient cohort as a whole the incremental cost-effectiveness ratio (ICER) was calculated to £8,998 per QALY gained i.e. within the £20,000/QALY cost-effectiveness benchmark used by the National Institute for Health and Clinical Excellence (NICE). The sensitivity analysis performed indicates that ICER values range from £15,829/QALY for the least severe patients through to TLA treatment being dominant i.e. cost saving as well as improving quality-of-life, for individuals with the most severe and poorly controlled asthma.

We are very pleased with the results that will be very valuable in our discussions with NHS and health care organisations within and outside the UK, says Fredrik Werner, CEO, Airsonett AB.

We use cookies to enhance your experience of our website. To view our privacy policy click here
I accept Cancel